Novosti
Khirurgii
This journal is
indexed in Scopus



Year 2008 Vol. 16 No 3

LECTURES, REVIEWS

MILYI M.N.

PHARMACOECONOMIC INVESTIGATIONS OF PROPHYLAXIS OF THE PERIOPERATIVE THROMBOTIC COMPLICATIONS BY ENOXAPARIN AND THEIR RELEVANCE FOR PUBLIC HEALTH OF THE REPUBLIC

Thromboembolic complications remain one of the leading causes of the mortality rate among surgical patients. Low molecular weight heparins are currently the most popular prophylactic method despite their high cost. Pharmacoeconomic investigations of heparins are performed in many countries. In these studies pharmacoeconomic advantages of enoxaparin over non-fractionated heparin and warfarin used for prophylaxis in the orthopedic surgery are well demonstrated in the USA, UK, Italy, Canada, and France. There are data about cost-effectiveness of enoxaparin for thromboprophylaxis in general surgery in Sweden and New Zealand. Transfer of the foreign pharmacoeconomic data into the Belarusian public health services meets several pressing problems to take into consideration and requires original pharmacoeconomic investigation.

Keywords: pharmacoeconomic investigation, low molecular weight heparins, enoxaparin.
p. 144 154 of the original issue
References
  1. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group // Br. J. Surg. 1997. Vol. 84, N 8. P. 1099-1103.
  2. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer / D. Bergqvist [et al.] // N. Engl. J. Med. 2002. Vol. 346, N 13. P. 975-980.
  3. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial / R. S. McLeod [et al.] // Ann. Surg. 2001. Vol. 233, N 3. P. 438-444.
  4. Caen, J. P. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial / J. P. Caen // Thromb. Haemost. 1988. Vol. 59, N 2. P. 216-220.
  5. Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin / D. Bergqvist [et al.] // Semin. Thromb. Hemost. 1990. Suppl. 19-24.
  6. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin / C. W. Francis [et al.] // J. Bone Joint Surg. Am. 1997. Vol. 79, N 9. P. 1365-1372.
  7. A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture / M. Monreal [et al.] / J. Trauma. 1989. Vol. 29, N 6. P. 873-875.
  8. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. The European Fraxiparin Study (EFS) Group // Br. J. Surg. 1988. Vol. 75, N 11. P. 1058-1063.
  9. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group / K. Hamulyak [et al.] // Thromb. Haemost. 1995. Vol. 74, N 6. P. 1428-1431.
  10. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin / P. F. Leyvraz [et al.] // BMJ. 1991. Vol. 303, N 6802. P. 543-548.
  11. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin / R. H. Jr. Fitzgerald [et al.] // J. Bone Joint Surg. Am. 2001. Vol. 83-A, N 6. P. 900-906.
  12. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge / C. W. Jr. Colwell [et al.] // J. Bone Joint Surg. Am. 1999. Vol. 81, N 7. P. 932-940.
  13. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group / P. C. Comp [et al.] // J. Bone Joint Surg. Am. 2001. Vol. 83-A, N 3. P. 336-345.
  14. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin / P. Fauno [et al.] // J. Bone Joint Surg. Am. 1994. Vol. 76, N 12. P. 1814-1818.
  15. Double-blind randomized comparative study of enoxaparin and standard heparin in the prevention of thromboembolic disease during insertion of total hip replacement / A. Planes [et al.] // Rev. Med. Interne. 1988. Vol. 9, N 3. P. 327-333.
  16. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group / C. W. Jr. Colwell [et al.] // Clin. Orthop. Relat. Res. 1995. Vol. 321. P. 19-27.
  17. Demicheli, V. Effectiveness estimates in economic evaluation / V. Demicheli, T. Jefferson, L. Vale // Evidence-based Health Economics: From effectiveness to efficiency in systematic review / eds. C. Donaldson, M. Mugford, L. Vale. London: BMJ Books, 2002. P. 89-98.
  18. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery / M. Drummond [et al.] // Br. J. Surg. 1994. Vol. 81. P. 1742-1746.
  19. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation / J. Menzin [et al.] // Ann. Pharmacother. 1994. Vol. 28. P. 271-275.
  20. Hawkins, D. W. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement / D. W. Hawkins, P. C. Langley, K. P. Krueger // Am. J . Health Syst. Pharm. 1997. Vol. 54. P. 1185-1190.
  21. Long-term costeffectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement / M. Marchetti [et al.] // Haematologica. 1999. Vol. 84. P. 730-737.
  22. Drummond, M. F. Basic types of economic evaluation / M. F. Drummond, G. L. Stoddart, G. W. Torrance // Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 1997. P. 6-26
  23. OBrien, B. J. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement / B. J. OBrien, D. R.. Anderson, R. Goeree // CMAJ. 1994. Vol. 150. P. 1083-1090.
  24. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deepvein thrombosis after total hip replacement surgery / J. Menzin [et al.] // Arch. Intern. Med. 1995. Vol. 155. P. 757-764.
  25. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo / A. Planes [et al.] // Lancet. 1996. Vol. 348. P. 224-228.
  26. Low-molecularweight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement / D. Bergqvist [et al.] // N. Engl. J. Med. 1996. Vol. 335. P. 696-700.
  27. Cost effectiveness of a low-molecular weight heparin in prophylaxis against prolonged deep vein thrombosis after total hip replacement / B. Detournay [et al.] // Pharmacoeconomics. 1998. Vol. 13. P. 81-89.
  28. D. Bergqvist Cost-effectiveness of prolonged administration of a low molecular weight heparin for the prevention of deep venous thrombosis (DVT) following total hip replacement / D. Bergqvist, B. Jnsson // Value Health. 1999. Vol. 2. P. 288-294.
  29. Economic evaluation of enoxaparin as post discharge prophylaxis for deep vein thrombosis in elective hip surgery / L. M. Davies [et al.] // Value Health. 2001. Vol. 3, N 6. P. 397-406.
  30. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery / E. Etchells [et al.] // Arch. Intern. Med. 1999. Vol. 159. P. 1221-1228.
  31. Lowmolecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis / M. T. Nurmohamed. [et al.] // Lancet. 1992. Vol. 340. P. 152-156.
  32. Heaton, D. Low molecular weight versus unfractionated heparin: a clinical and economic appraisal / D. Heaton, M. Pearce // Pharmacoeconomics. 1995. Vol. 8, N 2. P. 91-99.
  33. Bergqvist, D. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin / D. Bergqvist, B. Lindgren, T. Mtzsch // Br. J. Surg. 1996. Vol. 83. P. 1548-1552.
  34. Transferring economic evaluation results from setting to setting / M. F. Drummond [et al.] // Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 1997. P. 272-281.
  35. 35Cost analysis. Some basics / M. F. Drummond [et al.] // Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 1997. P. 52-68.
Contacts | ©Vitebsk State Medical University, 2007